Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Cyclophosphamide"

13 News Found

CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma
News | March 25, 2022

CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma

Recommendation is based on pivotal data from the phase III POLARIX study

VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
Drug Approval | January 20, 2022

VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis

First launches expected in H1 2022

Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Biotech | November 30, 2021

Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy

Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab

Latest Stories

Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging